Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription medications for them.

The Phase 2b studies will evaluate the safety, tolerability, and dose-frequency of A-101 45% compared with its vehicle. Approximately 240 patients will be randomized in the two double-blinded trials, which are being conducted at 30 investigational centers within the US.

"We are initiating these studies subsequent to a productive guidance meeting with the FDA," said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. "This is an important step forward as we advance our clinical program for A-101 45% in the treatment of common warts."